# Chemung Financial Corp: financial statements, quarterly

CHMG · Nasdaq · CIK 763563 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/chmg.md) · [Financials](/companies/chmg/financials.md) · [Filings](/companies/chmg/filings.md) · [Insiders](/companies/chmg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/chmg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest expense | $m | [11.0](/filings/0000763563-23-000079.md) | [12.1 d](/filings/0000763563-24-000043.md) | [13.1](/filings/0000763563-24-000060.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [2.1](/filings/0000763563-24-000079.md) | [0.8 d](/filings/0000763563-25-000058.md) | [2.0](/filings/0000763563-25-000074.md) | [1.3](/filings/0000763563-25-000103.md) | [1.5](/filings/0001628280-25-049947.md) | [1.6 d](/filings/0001628280-26-017546.md) | [1.7](/filings/0001628280-26-031834.md) | [(2.4)](/filings/0001628280-26-054168.md) | [2.3](/filings/0001628280-25-049947.md) | [3.3 d](/filings/0001628280-26-017546.md) | [2.6](/filings/0001628280-26-031834.md) | [2.5](/filings/0001628280-26-054168.md) |
| Net income | $m | [7.6](/filings/0000763563-24-000079.md) | [3.8 d](/filings/0000763563-25-000058.md) | [7.1](/filings/0000763563-25-000074.md) | [5.0](/filings/0000763563-25-000103.md) | [5.7](/filings/0001628280-25-049947.md) | [5.9 d](/filings/0001628280-26-017546.md) | [6.0](/filings/0001628280-26-031834.md) | [(6.5)](/filings/0001628280-26-054168.md) | [7.8](/filings/0001628280-25-049947.md) | [7.7 d](/filings/0001628280-26-017546.md) | [9.2](/filings/0001628280-26-031834.md) | [8.8](/filings/0001628280-26-054168.md) |
| Diluted EPS | $ per share | [1.61](/filings/0000763563-24-000079.md) | not reported | [1.48](/filings/0000763563-25-000074.md) | [1.05](/filings/0000763563-25-000103.md) | [1.19](/filings/0001628280-25-049947.md) | not reported | [1.26](/filings/0001628280-26-031834.md) | [(1.35)](/filings/0001628280-26-054168.md) | [1.62](/filings/0001628280-25-049947.md) | not reported | [1.91](/filings/0001628280-26-031834.md) | [1.82](/filings/0001628280-26-054168.md) |
| Basic EPS | $ per share | [1.61](/filings/0000763563-24-000079.md) | not reported | [1.48](/filings/0000763563-25-000074.md) | [1.05](/filings/0000763563-25-000103.md) | [1.19](/filings/0001628280-25-049947.md) | not reported | [1.26](/filings/0001628280-26-031834.md) | [(1.35)](/filings/0001628280-26-054168.md) | [1.62](/filings/0001628280-25-049947.md) | not reported | [1.91](/filings/0001628280-26-031834.md) | [1.82](/filings/0001628280-26-054168.md) |

- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [75.6](/filings/0000763563-23-000079.md) | [36.8](/filings/0000763563-25-000058.md) | [94.9](/filings/0000763563-24-000060.md) | [70.2](/filings/0000763563-24-000074.md) | [80.4](/filings/0000763563-24-000079.md) | [47.0](/filings/0001628280-26-017546.md) | [53.4](/filings/0000763563-25-000074.md) | [320](/filings/0000763563-25-000103.md) | [108](/filings/0001628280-25-049947.md) | [50.1](/filings/0001628280-26-054168.md) | [53.4](/filings/0001628280-26-031834.md) | [73.1](/filings/0001628280-26-054168.md) |
| Total assets | $m | [2,708](/filings/0000763563-24-000079.md) | [2,711](/filings/0000763563-25-000058.md) | [2,785](/filings/0000763563-25-000074.md) | [2,756](/filings/0000763563-25-000103.md) | [2,774](/filings/0001628280-25-049947.md) | [2,776](/filings/0001628280-26-017546.md) | [2,797](/filings/0001628280-26-031834.md) | [2,852](/filings/0001628280-26-054168.md) | [2,697](/filings/0001628280-25-049947.md) | [2,710](/filings/0001628280-26-054168.md) | [2,749](/filings/0001628280-26-031834.md) | [2,820](/filings/0001628280-26-054168.md) |
| Total liabilities | $m | [2,538](/filings/0000763563-23-000079.md) | [2,515](/filings/0000763563-25-000058.md) | [2,588](/filings/0000763563-24-000060.md) | [2,555](/filings/0000763563-24-000074.md) | [2,554](/filings/0000763563-24-000079.md) | [2,561](/filings/0001628280-26-017546.md) | [2,568](/filings/0000763563-25-000074.md) | [2,618](/filings/0000763563-25-000103.md) | [2,451](/filings/0001628280-25-049947.md) | [2,456](/filings/0001628280-26-054168.md) | [2,486](/filings/0001628280-26-031834.md) | [2,550](/filings/0001628280-26-054168.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [99.1](/filings/0000763563-25-000103.md) | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [170](/filings/0000763563-24-000079.md) | [195](/filings/0001628280-26-017546.md) | [197](/filings/0000763563-25-000103.md) | [201](/filings/0001628280-25-049947.md) | [221](/filings/0001628280-25-049947.md) | [215](/filings/0001628280-26-054168.md) | [228](/filings/0001628280-26-054168.md) | [235](/filings/0001628280-26-054168.md) | [245](/filings/0001628280-25-049947.md) | [255](/filings/0001628280-26-054168.md) | [263](/filings/0001628280-26-054168.md) | [270](/filings/0001628280-26-054168.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [9.4 d](/filings/0000763563-24-000079.md) | [3.6 d](/filings/0000763563-25-000058.md) | [7.9](/filings/0000763563-25-000074.md) | [6.5 d](/filings/0000763563-25-000103.md) | [9.2 d](/filings/0001628280-25-049947.md) | [6.2 d](/filings/0001628280-26-017546.md) | [7.2](/filings/0001628280-26-031834.md) | [9.7 d](/filings/0001628280-26-054168.md) | [12.2 d](/filings/0001628280-25-049947.md) | [16.3 d](/filings/0001628280-26-017546.md) | [9.0](/filings/0001628280-26-031834.md) | [9.2 d](/filings/0001628280-26-054168.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000763563-24-000079.md) | [0.0 d](/filings/0000763563-25-000058.md) | [0.1](/filings/0000763563-25-000074.md) | [1.0 d](/filings/0000763563-25-000103.md) | [0.6 d](/filings/0001628280-25-049947.md) | [1.9 d](/filings/0001628280-26-017546.md) | [0.3](/filings/0001628280-26-031834.md) | [0.4 d](/filings/0001628280-26-054168.md) | [0.4 d](/filings/0001628280-25-049947.md) | [0.6 d](/filings/0001628280-26-017546.md) | [0.1](/filings/0001628280-26-031834.md) | [0.3 d](/filings/0001628280-26-054168.md) |
| Dividends paid | $m | [1.5 d](/filings/0000763563-24-000079.md) | [1.5 d](/filings/0000763563-25-000058.md) | [1.5](/filings/0000763563-25-000074.md) | [1.5 d](/filings/0000763563-25-000103.md) | [2.9 d](/filings/0001628280-25-049947.md) | [1.5 d](/filings/0001628280-26-017546.md) | [1.5](/filings/0001628280-26-031834.md) | [1.5 d](/filings/0001628280-26-054168.md) | [1.6 d](/filings/0001628280-25-049947.md) | [1.6 d](/filings/0001628280-26-017546.md) | [1.6](/filings/0001628280-26-031834.md) | [1.6 d](/filings/0001628280-26-054168.md) |
| Share repurchases | $m | [0.0 d](/filings/0000763563-24-000079.md) | [0.2 d](/filings/0000763563-25-000058.md) | [0.1](/filings/0000763563-25-000074.md) | [0.0 d](/filings/0000763563-25-000103.md) | [0.0 d](/filings/0001628280-25-049947.md) | [0.3 d](/filings/0001628280-26-017546.md) | [0.1](/filings/0001628280-26-031834.md) | [0.0 d](/filings/0001628280-26-054168.md) | [0.0 d](/filings/0001628280-25-049947.md) | [0.3 d](/filings/0001628280-26-017546.md) | [0.2](/filings/0001628280-26-031834.md) | [0.0 d](/filings/0001628280-26-054168.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [4,692](/filings/0000763563-23-000079.md) | [4,721](/filings/0000763563-24-000060.md) | [4,729](/filings/0000763563-24-000074.md) | [4,736](/filings/0000763563-24-000079.md) | [4,764](/filings/0000763563-25-000074.md) | [4,770](/filings/0000763563-25-000103.md) | [4,773](/filings/0001628280-25-049947.md) | [4,791](/filings/0001628280-26-031834.md) | [4,808](/filings/0001628280-26-054168.md) | [4,811](/filings/0001628280-25-049947.md) | [4,825](/filings/0001628280-26-031834.md) | [4,838](/filings/0001628280-26-054168.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,821,472 at 2026-08-01, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-054168.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.